vs
Amphastar Pharmaceuticals, Inc.（AMPH）とProto Labs Inc（PRLB）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $139.3M、Proto Labs Incの約1.3倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 5.8%、差は7.5%）。Proto Labs Incの前年同期比売上増加率が高い（10.4% vs -1.8%）。過去8四半期でProto Labs Incの売上複合成長率が高い（5.3% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Proto Labsは各種業界向けに迅速な部品製造サービスを提供する企業です。3Dプリント、CNC加工、板金加工、射出成形により、試作開発から量産まで対応可能なオーダーメイド部品を生産します。製品は医療機器、航空宇宙、電子機器、家電、自動車、消費財など多様な分野で活用されており、本社は米国ミネソタ州にあり、米国内各地に生産拠点を擁しています。
AMPH vs PRLB — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $139.3M |
| 純利益 | $24.4M | $8.1M |
| 粗利率 | 46.8% | 45.6% |
| 営業利益率 | 19.4% | 7.1% |
| 純利益率 | 13.3% | 5.8% |
| 売上前年比 | -1.8% | 10.4% |
| 純利益前年比 | -35.7% | 125.4% |
| EPS（希薄化後） | $0.51 | $0.29 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $139.3M | ||
| Q4 25 | $183.1M | $136.5M | ||
| Q3 25 | $191.8M | $135.4M | ||
| Q2 25 | $174.4M | $135.1M | ||
| Q1 25 | $170.5M | $126.2M | ||
| Q4 24 | $186.5M | $121.8M | ||
| Q3 24 | $191.2M | $125.6M | ||
| Q2 24 | $182.4M | $125.6M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $7.2M | ||
| Q2 25 | $31.0M | $4.4M | ||
| Q1 25 | $25.3M | $3.6M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $7.2M | ||
| Q2 24 | $37.9M | $4.5M |
| Q1 26 | — | 45.6% | ||
| Q4 25 | 46.8% | 44.2% | ||
| Q3 25 | 51.4% | 45.3% | ||
| Q2 25 | 49.6% | 44.3% | ||
| Q1 25 | 50.0% | 44.1% | ||
| Q4 24 | 46.5% | 42.7% | ||
| Q3 24 | 53.3% | 45.6% | ||
| Q2 24 | 52.2% | 45.0% |
| Q1 26 | — | 7.1% | ||
| Q4 25 | 19.4% | 5.0% | ||
| Q3 25 | 13.2% | 6.5% | ||
| Q2 25 | 24.2% | 3.7% | ||
| Q1 25 | 21.9% | 3.6% | ||
| Q4 24 | 24.2% | -1.2% | ||
| Q3 24 | 29.8% | 6.8% | ||
| Q2 24 | 30.3% | 4.8% |
| Q1 26 | — | 5.8% | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 5.3% | ||
| Q2 25 | 17.8% | 3.3% | ||
| Q1 25 | 14.8% | 2.9% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 5.7% | ||
| Q2 24 | 20.8% | 3.6% |
| Q1 26 | — | $0.29 | ||
| Q4 25 | $0.51 | $0.25 | ||
| Q3 25 | $0.37 | $0.30 | ||
| Q2 25 | $0.64 | $0.18 | ||
| Q1 25 | $0.51 | $0.15 | ||
| Q4 24 | $0.74 | $-0.01 | ||
| Q3 24 | $0.78 | $0.29 | ||
| Q2 24 | $0.73 | $0.18 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $124.0M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $683.1M |
| 総資産 | $1.6B | $778.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $124.0M | ||
| Q4 25 | $282.8M | $128.1M | ||
| Q3 25 | $276.2M | $119.2M | ||
| Q2 25 | $231.8M | $103.2M | ||
| Q1 25 | $236.9M | $96.8M | ||
| Q4 24 | $221.6M | $103.1M | ||
| Q3 24 | $250.5M | $100.5M | ||
| Q2 24 | $217.8M | $112.9M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $683.1M | ||
| Q4 25 | $788.8M | $673.9M | ||
| Q3 25 | $776.7M | $664.7M | ||
| Q2 25 | $757.5M | $664.7M | ||
| Q1 25 | $751.3M | $656.8M | ||
| Q4 24 | $732.3M | $670.2M | ||
| Q3 24 | $727.7M | $680.0M | ||
| Q2 24 | $713.3M | $685.2M |
| Q1 26 | — | $778.6M | ||
| Q4 25 | $1.6B | $763.4M | ||
| Q3 25 | $1.7B | $756.9M | ||
| Q2 25 | $1.6B | $743.3M | ||
| Q1 25 | $1.6B | $737.5M | ||
| Q4 24 | $1.6B | $743.5M | ||
| Q3 24 | $1.5B | $753.8M | ||
| Q2 24 | $1.5B | $758.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $17.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | — |
| FCFマージンFCF / 売上 | 13.4% | — |
| 設備投資強度設備投資 / 売上 | 4.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 2.16× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $17.5M | ||
| Q4 25 | $32.9M | $16.5M | ||
| Q3 25 | $52.6M | $29.1M | ||
| Q2 25 | $35.6M | $10.6M | ||
| Q1 25 | $35.1M | $18.4M | ||
| Q4 24 | $29.0M | $17.3M | ||
| Q3 24 | $60.0M | $24.8M | ||
| Q2 24 | $69.1M | $14.4M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $8.4M | ||
| Q3 25 | $47.2M | $25.0M | ||
| Q2 25 | $25.0M | $9.1M | ||
| Q1 25 | $24.4M | $17.1M | ||
| Q4 24 | $16.6M | $16.5M | ||
| Q3 24 | $46.2M | $23.2M | ||
| Q2 24 | $63.1M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 6.2% | ||
| Q3 25 | 24.6% | 18.5% | ||
| Q2 25 | 14.3% | 6.7% | ||
| Q1 25 | 14.3% | 13.6% | ||
| Q4 24 | 8.9% | 13.5% | ||
| Q3 24 | 24.1% | 18.5% | ||
| Q2 24 | 34.6% | 8.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 5.9% | ||
| Q3 25 | 2.8% | 3.0% | ||
| Q2 25 | 6.1% | 1.1% | ||
| Q1 25 | 6.3% | 1.0% | ||
| Q4 24 | 6.7% | 0.7% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 3.3% | 3.3% |
| Q1 26 | — | 2.16× | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 4.03× | ||
| Q2 25 | 1.15× | 2.39× | ||
| Q1 25 | 1.39× | 5.11× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 3.44× | ||
| Q2 24 | 1.82× | 3.18× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRLB
| CNC Machining | $63.2M | 45% |
| Injection Molding | $51.1M | 37% |
| 3D Printing | $20.5M | 15% |
| Sheet Metal | $4.4M | 3% |
| Other Revenue | $207.0K | 0% |
